China revokes Gilead’s patent for key HIV drug

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

China revokes Gilead’s patent for key HIV drug

SIPO’s Patent Reexamination Board has revoked Gilead’s patent for Viread following an opposition from domestic manufacturer Arisco

The Patent Reexamination Board found that Gilead’s application lacked novelty. Viread (tenofovir) was discovered in 1985 and is considered a front line drug for AIDS treatment.

China for many years has had provisions in its laws allowing for compulsory licences, though none have been issued. Last May, China issued its Measures for Compulsory Licensing of Patent Implementation, which brought about concerns that China would follow India’s lead in aggressively issuing such licences.

Though China has not yet handed out a compulsory licence, many believe that the government uses the provision to increase leverage in negotiations with drug companies. Last year, reports indicated that Gilead was concerned that Viread would be targeted and offered to make donations of the drug to head off the attempt.

A number of other jurisdictions have also taken steps to increase access to the drug. India and Brazil have rejected patents for tenofovir, while Indonesia took a compulsory licence for the drug. Gilead also licenses the patent to the Medicines Patent Pool in order to help increase access to the drug in certain developing economies.

more from across site and ros bottom lb

More from across our site

Suspicions concerning AI in the legal space, and another copyright win for Ed Sheeran were among the biggest IP developments this week
Michael Sitzman, a life sciences litigator, explains how McDermott’s busy schedule at the UPC convinced him to join
The UK’s top court will hand down the decision next week, 17 months after hearing arguments in the crucial trademark dispute
Ceyda Maisami explains why HP is becoming more vocal in its SEP arguments and reveals why the company has transformed the way it engages with outside counsel
In the latest UPC update, we examine a ruling on director liability, another on the Gillette defence, and look ahead to cases concerning medical devices
Burak Yüceel outlines six characteristics that make a successful IP practitioner and explains why Alan Turing is an inspiration
Lawyers at Dentons unpick the findings of a survey that revealed that businesses tend to focus on reactive rather than proactive use of AI when performing IP evaluations
Peng Lei and David Webb of Herbert Smith Freehills assess what battery innovators need to know to protect their investments
Little to no policies from either candidate suggest we may be waiting a while before we see major changes to the US’s IP framework
Marks & Clerk was accused of receiving ‘secret commissions’ from CPA Global in exchange for securing referrals for IP services
Gift this article